ABout US

Computational chemists. Drug designers. Paradigm changers. Learn more about who we are.

Core Tenets of Nimbus’ Mission

  • Medicines are our mission.
  • We are building a great company that will make important contributions to human health and provide value to our investors and collaborators.
  • Our focus is unmet medical need and high-value targets in the metabolism-oncology-immunology triad.
  • Nimbus is fully committed to computational chemistry and the symbiotic relationship with our co-founder, Schrödinger, and continues to build and partner to establish new capabilities that advance drug discovery and development.
  • Our company is capable of moving novel medicines to registration, but will also be willing to partner when appropriate.

board of directors

Bruce Booth, Ph.D.

Chairman of the Board
Partner, Life Sciences
Atlas Venture

VIEW bio
Chris Christoffersen, Ph.D.

General Partner
Lightstone Ventures

VIEW bio
Ramy Farid, Ph.D.

President & CEO
Schrödinger

VIEW bio
Brian M. Gallagher, Jr., Ph.D.

Partner
SR One Ltd.

VIEW bio
Steve Hall, Ph.D.

General Partner
Lilly Ventures

VIEW bio
Mark Iwicki

Chairman and CEO
Kala Pharmaceuticals

VIEW bio
Elaine V. Jones, Ph.D.

Vice President, Venture Capital
Pfizer Venture Investments

VIEW bio
Donald W. Nicholson, Ph.D.

CEO
Nimbus Therapeutics

VIEW bio
George P. Vlasuk, Ph.D.

President and CEO
Navitor Pharmaceuticals

VIEW bio

SCIENTIFIC ADVISORS & COLLABORATORS

Metabolic Diseases/NASH
  • Arun Sanyal, M.D.Virginia Commonwealth University
  • Scott Friedman, M.D.Mt. Sinai Hospital
  • Stephen Harrison, M.D.Brooke Army Medical
  • Brent Tetri, M.D.St. Louis University
  • Rohit Loomba, M.D.UC San Diego
  • James Harwood, Ph.D.Pfizer (retired)
  • Tom Hughes, Ph.D.Zagen, Novartis
Oncology
  • Lou Staudt, M.D., Ph.D.National Cancer Institute
  • Jennifer Brown, M.D., Ph.D.Dana-Farber Cancer Institute
  • Reuben Shaw, Ph.D.Salk Institute
  • Bryan C. Fuchs, Ph.D.Massachusetts General Hospital
  • Kenneth Kenji Tanabe, M.D.Massachusetts General Hospital
  • A. Thomas Look, M.D.Dana-Farber Cancer Institute
  • David Tuveson, M.D., Ph.D.Cold Spring Harbor Laboratory
Inflammation
  • Robert A. Lewis, M.D.Aventis, Syntex (retired)
  • Luke O’Neill, Ph.D.University College Dublin
  • Xiaoxia Li, Ph.D.Cleveland Clinic
  • David A. Fruman, Ph.D.UC Irvine
  • Robert Inman, M.D.University of Toronto

Investors

Nimbus Therapeutics is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments and Lightstone Ventures. The company closed a $24 million Series A financing in June 2011 and a $43 million Series B financing in March 2015.

x

Bruce Booth, Ph.D.

Chairman of the Board
Partner, Life Sciences
Atlas Venture

Dr. Bruce Booth is a Partner in the Life Sciences group at Atlas Venture. He joined in 2005 and focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies.

Bruce currently serves on the Boards of Atlas portfolio companies Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has worked closely with portfolio companies ARCA Biopharma (NASD:ABIO), Archemix, NxStage Medical (NASD:NXTM), Prestwick (acquired by Biovail, Sept 2008), Proprius (acquired by Cypress Biosciences, Feb 2008) and Stromedix.

Previously, Bruce was a Principal at Caxton Health Holdings L.L.C., where he focused on the firm’s private equity activities, ranging from early stage venture capital through late stage private equity. Prior to Caxton, he was an Associate Principal at McKinsey & Company, where he advised biopharmaceutical clients on R&D productivity, corporate strategy and business development issues.

As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University’s Nuffield Department of Medicine and the Weatherall Institute of Molecular Medicine. He received his Bachelor of Science degree summa cum laude in Biochemistry from the Pennsylvania State University.

He serves as a Trustee of the New York Academy of Medicine, where he participates on the Executive Committee as Treasurer and helps manage the Academy’s Endowment. He also currently serves in several life sciences advisory roles, including UCB Pharma NewMedicines Science Advisory Board, Beth Israel Deaconess Medical Center’s Accelerating Bench to Bedside effort, and LifeTech Boston seed-stage loan program. Bruce has authored numerous scientific papers and biotech venture capital review articles, including several in Nature Biotechnology and Nature Reviews Drug Discovery.

Chris Christoffersen, Ph.D.

General Partner
Lightstone Ventures

Dr. Chris Christoffersen is a General Partner of Lightstone Ventures. He focuses on biopharmaceutical investments out of the firm’s Boulder, CO, office. Chris joined Morgenthaler in 2001 and serves as a General Partner. His signature deals include Avidia (acquired by Amgen in 2006), Threshold (NASDAQ: THLD), Morphotek (acquired by Easai in 2007), and FoldRx (acquired by Pfizer in 2010). He serves on the boards of Catalyst BioSciences, Galleon Pharmaceuticals, Tragara Pharmaceuticals, Stemgent, Elcelyx, and Nimbus Therapeutics. Chris brings to Lightstone more than 20 years of operations experience, having served as CEO and President of Ribozyme Pharmaceuticals (a/k/a Sirna Therapeutics; acquired by Merck for $1.2B), Senior Vice President of Research at SmithKline Beecham, Vice President of Discovery Research at The Upjohn Company, and President of Colorado State University.

Chris is a recognized thought leader in the field of biotechnology. He received an honorary doctor of law degree from Cornell College in 1983, the Outstanding Research of Year Award from the International Society of Quantum Biology in 1981, the W. E. Upjohn Award for contributions in biotechnology in 1988, and a Lifetime Achievement Award in 2003 from the Colorado Biosciences Association.

Ramy Farid, Ph.D.

President & CEO
Schrödinger

Dr. Ramy Farid joined Schrödinger in 2002 and serves as President & CEO and as a member of the board of directors. Prior to joining Schrödinger, Ramy was an Assistant Professor in the Chemistry Department at Rutgers University. He was an NIH Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his Ph.D. in Chemistry from Caltech.

Brian M. Gallagher, Jr., Ph.D.

Partner
SR One Ltd.

Dr. Brian M. Gallagher is a Partner at SR One Ltd. He established the SR One Boston office in 2010 and is focused on building innovative therapeutic and life science companies. Brian currently represents SR One on the boards of Aileron Therapeutics, CalciMedica, Constellation Pharmaceuticals, Navitor Pharmaceuticals, Nimbus Therapeutics, RaNA Therapeutics, and River Vision. He previously led the firm’s investments in Dicerna Pharmaceuticals (NASDAQ: DRNA), Spero Therapeutics and SpringLeaf Therapeutics. Brian has nearly 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies.

Brian joined SR One from Sirtris Pharmaceuticals, where he was responsible for corporate development, operations and post-merger integration following the $720 million acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian was with Alantos Pharmaceuticals where he played key roles in the R&D and business development activities, and led many aspects of the post-merger integration following the $300 million acquisition of Alantos by Amgen in 2007. Brian began his career in R&D at Eisai where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas.

Brian is an inventor on more than 25 patents and patent applications, and is the senior author of a number of scientific publications. He currently serves on the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society, as a mentor for MassBio MassCONNECT program, and as a peer reviewer/editorial board member for numerous journals and research funding authorities.

Brian received his M.S. and Ph.D. degrees in Organic Chemistry from the University of Michigan, and a B.S. in Chemistry from the University of Massachusetts where he was a Shapiro scholar.

Steve Hall, Ph.D.

General Partner
Lilly Ventures

Dr. Steve Hall brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Steve was the co-founder and Senior Vice President, Research and Development, at Serenex, Inc. There, he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years. This novel, orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly, where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research and information technology. There, he was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75 million. Steve currently sits on the boards of FORMA Therapeutics, Hydra Biosciences, InnoCentive, Nimbus Therapeutics and Cerulean Pharma. He also is a board observer at Avid Radiopharmaceuticals and Viamet.

Steve is the author of more than 40 papers and 60 papers and 60 patients. He received his B.S. in Chemistry from Central Michigan University and his Ph.D. in organic chemistry from the Massachusetts Institute of Technology.

Mark Iwicki

Chairman and CEO
Kala Pharmaceuticals

Mark Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Prior to joining Civitas, he was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He also served as President and CEO of Sunovion Pharmaceuticals, where he provided leadership for the successful launch of that company, which was created following the acquisition of Sepracor by Dainippon Sumitomo Pharmaceuticals. Mark also previously held key senior leadership roles with Sepracor and Novartis Pharmaceuticals. He currently also sits on the board of directors for Kala Pharmaceuticals, Allergen Research Corporation and Taris Biomedical.

Elaine V. Jones, Ph.D.

Vice President, Venture Capital
Pfizer Venture Investments

Dr. Elaine V. Jones joined Pfizer Venture Investments in 2008. She is responsible for making and managing venture investments for Pfizer and currently oversees the PVI investments in Autifony Therapeutics Ltd. (London, UK), CytomX Therapeutics (San Francisco, CA), Mersana Therapeutics (Cambridge, MA), Merus B.V. (Utrecht, The Netherlands), MIRNA Therapeutics (Austin, TX), Mission Therapeutics (Cambridge, UK), Nimbus Therapeutics LLC. (Cambridge, MA), Quartet Medicine (Cambridge, MA), and Ziarco Pharma (Canterbury, UK). Elaine brings 15 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team.

Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.

Prior to joining ESR, Elaine began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron. Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D.

Elaine is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.

Donald W. Nicholson, Ph.D.

CEO
Nimbus Therapeutics

Dr. Don Nicholson is the Chief Executive Officer and board member of Nimbus. He joined from Merck where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious diseases and neurosciences. He began his career in 1988 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Don has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally-recognized for his contributions to the field of apoptotic cell death. He received his Ph.D. and an Honors B.Sc. degree in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.

George P. Vlasuk, Ph.D.

President and CEO
Navitor Pharmaceuticals

Dr. George P. Vlasuk is a scientifically trained executive with nearly 30 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. George currently is President and CEO at Navitor Pharmaceuticals. Before joining Navitor, he served as CEO of Sirtris, a GlaxoSmithKline Company. Prior to Sirtris, George was Vice President, Metabolic Disease and Hemophilia Research, at Wyeth Pharmaceuticals. George also previously served as Chief Scientific Officer and Executive Vice President of Research and Development at Corvas International, prior to the merger of Corvas and Dendreon Corporation. Earlier in his career, George led a research team at Merck and Co., and was responsible for multiple discovery programs in the field of cardiovascular medicine. George is the author of more than 100 peer-reviewed scientific publications, book chapters and reviews, and 38 issued U.S. and foreign patents.

location

784 Memorial Drive, Suite 100
Cambridge, MA 02139
USA

call US

857-999-2009